BUSINESS
Zydus Lifesciences in licensing deal with America's Agenus for cancer therapy
The agreement grants Zydus the rights to Agenus' next-generation immunotherapy platform, which is designed to enhance and sustain the immune system's fight against tumor cells.
BUSINESS
Glenmark’s myeloma drug delivers high response in phase-1 trial
At active dose levels (≥ 50 µg/kg), 26 of 33 evaluable patients (79%) achieved objective responses, including stringent or complete remissions in 30%, the company said.
BUSINESS
Trump drug pricing order to have limited credit impact on Indian pharma: CRISIL
The report says exports to the U.S. are dominated by generics, which already account for 90% of prescription volumes but just 13% of value, and are priced lower than in peer nations.
BUSINESS
Apollo Hospitals ready with Rs 8,000-crore expansion plan, to add 2,000 beds this fiscal
India's biggest healthcare player will likely have its new facilities in Bengaluru, Hyderabad, Gurugram, Kolkata and New Delhi up and running in the second half of FY26
BUSINESS
Delhi High Court restrains Dr.Reddy’s, OneSource from domestic sale of weight loss drug amid patent dispute
Justice Amit Bansal, presiding over the matter, recorded the defendants’ undertaking that they would not sell the impugned drug in India until the next hearing, scheduled for August 19, 2025. The court also took note of Novo Nordisk’s contention that even the export of an infringing product constitutes patent infringement under Indian law.
BUSINESS
Sun Pharma completes its acquisition of Checkpoint Therapeutics
Checkpoint Therapeutics is a Nasdaq-listed company focused on developing treatments for solid tumor cancers, including UNLOXCYT. The deal was valued at $355 million in cash and milestone payments.
BUSINESS
Apollo Hospitals Q4 net profit jumps 54% on strong hospitals, digital growth
The company also announced a major expansion plan and a final dividend of ₹10 per share.
TRENDS
Servier India ends exclusive distribution pact with Entero amid monopoly concerns
The move comes after the All India Organisation of Chemists and Druggists (AIOCD) raised red flags about the deal, warning that such exclusivity could lead to market distortion, reduced competition, and medicine shortages.
BUSINESS
Dr Reddy's targets new launches, potential M&A as gRevlimid tapers off in America
Dr Reddy's CFO Narasimham recently told to Moneycontrol he is confident of 'sustained double-digit sales growth' in FY26, with EBITDA and Return on Capital Employed (ROCE) at 25% or above. Some analysts are circumspect about the ability to fully offset the 'gRevlimid void' in the medium term.
BUSINESS
In Sickness & In Health: Lilly, Apollo Hospitals join forces to tackle obesity, diabetes
The collaboration will span over 200 Apollo clinics and involve 300 medical practitioners, focusing on patient education, healthcare provider training, and infrastructure development.
BUSINESS
Alkem Laboratories net profit rises 4.2% to ₹305.9 crore in Q4FY25
BUSINESS
IKS Health CEO sees growth surge for tech services as US govt drives down healthcare spends
The total TAM (total addressable market) is about $225 billion, of which only $34 billion has been outsourced, Gupta said in a recent interview
BUSINESS
Novo Nordisk to launch blockbuster obesity drug Wegovy in India soon
"We are introducing Wegovy (injectable Semaglutide 2.4 mg) this year, which offers full therapeutic strengths of semaglutide for comprehensive weight management and obesity treatment," the company told Moneycontrol in an email statement.
BUSINESS
Akums Q4 net profit drops 4.3% despite revenue growth
For the full year FY25, total income rose 1% YoY to ₹4,170 crore, adjusted EBITDA was flat at ₹513 crore and margin rose slightly to 12.3%.
BUSINESS
India sees uptick in COVID cases. What are the symptoms, should you be worried?
Two new Omicron sub-variants, LF.7 and NB.1.8, are behind the rise in cases, which have crossed the 1,000 mark
BUSINESS
Glenmark Q4 net profit rises 11% on strong Europe sales
“Our performance reflects the underlying resilience of our business and the strength of our diversified portfolio,” said Glenn Saldanha, Chairman & MD. “We are committed to building on this momentum in FY26, with a sharper focus on innovation and global scale.”
BUSINESS
Sun Pharma sees mid-to-high single-digit growth in FY26, bets big on specialty expansion
The company also expects R&D spending to rise to 6–8% of sales, reflecting its commitment to pipeline expansion and innovation.
BUSINESS
Strides Pharma Q4 net profit surges 5x on strong US sales
Strides also reduced its net debt by Rs 512.8 crore, bringing the net debt-to-EBITDA ratio down to 1.9x. The board recommended a dividend of Rs 4 per share for FY25.
BUSINESS
Emcure net profit zooms 63% to Rs 197 crore in Q4FY25
The international segment recorded a 15.6 percent year-over-year growth in sales, reaching Rs 1,187 crore. This was significantly bolstered by a robust 39.3 percent growth in the rest of the world segment.
BUSINESS
Antara Senior Care to invest Rs 500 crore to expand capacity fourfold
The company plans to ramp up its care home bed capacity to 2,000 beds and develop 10–12 new senior living communities.
BUSINESS
Mankind Pharma's Q4 net profit drops 10% to Rs 477 crore on one-off costs
The company has a net debt of Rs 5,784 crore, which translates into net debt to adjusted EBITDA ratio of 1.8x.
BUSINESS
Aster DM Healthcare Q4 net profit jumps 21% on margin gains; merger with Quality Care advances
Revenue for Q4 FY25 rose 2% YoY to Rs 1,000 crore, while operating EBITDA grew 16% to Rs 193 crore.
BUSINESS
Gland Pharma Q4 net profit slips 3% as US sales moderate; focus shifts to complex injectables, CDMO growth
“FY25 was a year of strategic realignment and investment in future growth,” said Executive Chairman Srinivas Sadu.
BUSINESS
Zydus targets FY26 expansion, but warns of slower US momentum post-Revlimid peak
The US business, a significant contributor to its revenue, is projected for single-digit growth in FY26.
